• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LENALIDOMIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • LENALIDOMIDE chembl:CHEMBL848 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    LENALIDOMIDE
    SYP-1512
    CC-5013
    REVLIMID
    CDC-501
    1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-AMINOISOINDOLINE
    CDC 501
    IMID3
    REVLIMID®
    3-(4-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE
    IMID-1
    rxcui:342369
    pubchem.compound:216326
    chembl:CHEMBL848
    chemidplus:191732-72-6
    drugbank:00480

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    (4 More Sources)

    Publications:

    Bertino et al., 2016, A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer., Mol. Cancer Ther.
    Wróbel T et al., 2017, <i>bFGF</i> Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients., Anticancer Res
    Melchert et al., 2007, The thalidomide saga., Int. J. Biochem. Cell Biol.
    Akobeng et al., 2009, Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease., Cochrane Database Syst Rev
    Zhu et al., 2013, Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma., Leuk. Lymphoma
    Egan et al., 2013, Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease., Br. J. Haematol.
    Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res
    Krönke et al., 2014, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells., Science
    Jakobsen Falk I et al., 2018, Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial., Cancer Chemother Pharmacol
  • LENALIDOMIDE   CRBN

    Interaction Score: 3.53

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor
    Direct Interaction yes

    PMIDs:
    22966948 23480694


    Sources:
    ChemblInteractions CIViC

  • LENALIDOMIDE   TNFSF11

    Interaction Score: 3.31

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Revlimid

    PMIDs:
    17369076 19370685


    Sources:
    TdgClinicalTrial

  • LENALIDOMIDE   DDB1

    Interaction Score: 1.47

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LENALIDOMIDE   IKZF1

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type multiple myeloma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    24292625


    Sources:
    JAX-CKB

  • LENALIDOMIDE   CUL4A

    Interaction Score: 1.47

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LENALIDOMIDE   VEGFB

    Interaction Score: 1.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial

  • LENALIDOMIDE   RBX1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LENALIDOMIDE   VEGFC

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial

  • LENALIDOMIDE   CTNNB1

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26521987


    Sources:
    PharmGKB

  • LENALIDOMIDE   FGF2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28373444


    Sources:
    PharmGKB

  • LENALIDOMIDE   TNF

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial TTD

  • LENALIDOMIDE   VEGFA

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial

  • LENALIDOMIDE   KRAS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + lenalidomide
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive

    PMIDs:
    27458141


    Sources:
    JAX-CKB

  • LENALIDOMIDE   ABCB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29177954


    Sources:
    PharmGKB

  • TdgClinicalTrial: LENALIDOMIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: lenalidomide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Jakobsen Falk I et al., 2018, Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial., Cancer Chemother Pharmacol
    Wróbel T et al., 2017, <i>bFGF</i> Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients., Anticancer Res
    Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res

  • JAX-CKB: lenalidomide

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Krönke et al., 2014, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells., Science
    Bertino et al., 2016, A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer., Mol. Cancer Ther.

  • CIViC: LENALIDOMIDE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Egan et al., 2013, Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease., Br. J. Haematol.

  • TTD: Lenalidomide

    • Version: 2020.06.01

    Alternate Names:
    D0Q5NX TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL848

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: LENALIDOMIDE

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL848

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21